117 related articles for article (PubMed ID: 15086737)
1. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.
Abargel A; Avinoach I; Kravtsov V; Boaz M; Glezerman M; Menczer J
Int J Gynecol Cancer; 2004; 14(2):354-9. PubMed ID: 15086737
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-kit in uterine carcinosarcoma.
Menczer J; Kravtsov V; Levy T; Berger E; Glezerman M; Avinoach I
Gynecol Oncol; 2005 Jan; 96(1):210-5. PubMed ID: 15589603
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous expression of the ras p21 and p53 proteins in human endometrial carcinomas.
Miturski R; Semczuk A; Jakowicki J
Acta Histochem; 1996 Nov; 98(4):411-8. PubMed ID: 8960305
[TBL] [Abstract][Full Text] [Related]
4. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.
Briese J; Schulte HM; Sajin M; Bamberger C; Redlin K; Milde-Langosch K; Löning T; Bamberger AM
Virchows Arch; 2008 Jul; 453(1):89-96. PubMed ID: 18415123
[TBL] [Abstract][Full Text] [Related]
5. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
6. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
7. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.
Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H
Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942
[TBL] [Abstract][Full Text] [Related]
8. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
9. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
[TBL] [Abstract][Full Text] [Related]
10. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
11. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
12. COX-2 expression in uterine carcinosarcoma.
Menczer J; Schreiber L; Sukmanov O; Kravtsov V; Berger E; Golan A; Levy T
Acta Obstet Gynecol Scand; 2010; 89(1):120-5. PubMed ID: 19900134
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma?
Chiyoda T; Tsuda H; Tanaka H; Kataoka F; Nomura H; Nishimura S; Takano M; Susumu N; Saya H; Aoki D
Genes Chromosomes Cancer; 2012 Mar; 51(3):229-39. PubMed ID: 22072501
[TBL] [Abstract][Full Text] [Related]
14. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.
Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S
Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541
[TBL] [Abstract][Full Text] [Related]
16. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
Lee SJ; Kim HS; Kim HS; Chun YK; Hong SR; Lee JH
Hum Pathol; 2007 Aug; 38(8):1226-31. PubMed ID: 17490723
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
19. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
20. p53 expression in tissue adjacent to endometrial carcinoma.
Shem EB; Fintsi Y; Avinoach I; Glezerman M; Menczer J
Eur J Gynaecol Oncol; 2002; 23(6):548-50. PubMed ID: 12556102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]